COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR

1 . A compound of Formula (I):

or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein:

R 1 is phenyl, heteroaryl, cycloalkyl, or heterocycloalkyl, wherein R 1 is substituted with 0-1 G 1 groups and 0-4 G 2 groups;

X is —C(O)— or —S(O) 2 —;

G 1 is —S(O) 2 alkyl, cycloalkyl optionally substituted with one or more R 5 , or phenyl optionally substituted with one or more R 5 ;

each G 2 is independently selected from halogen, OH, CN, alkyl optionally substituted with one or more R 5 , alkoxy optionally substituted with one or more R 5 ;

each R 2 is independently H, halogen, —C(O)O-alkyl or C 1 -C 3 alkyl optionally substituted with 1-3 halogens or two R 2 groups together with the carbon to which they are attached can form —CO— provided that not more than one R 2 is —C(O)O-alkyl;

L is —O—, —OC(R 8 ) 2 —, —N(R 6 )—, —N(R 6 )—C(R 8 ) 2 , —[C(R 8 ) 2 ] 1-2 —, —C(R 8 ) 2 O—, or —C(R 8 ) 2 —N(R 6 )—;

R 3 is H, halogen, alkyl, hydroxyalkyl, or haloalkyl;

R 4 is H, halogen, alkyl, hydroxyalkyl, heterocycloalkylalkyl, heteroarylalkyl, or -alkyl-N(R 6 ) 2 , wherein each alkyl, hydroxyalkyl, heterocycloalkylalkyl, heteroarylalkyl, -alkyl-N(R 6 ) 2 is optionally substituted with 1-3 R 7 ;

each R 5 is independently halogen or OH;

each R 6 is independently H or alkyl optionally substituted with one or more R 5 ;

each R 7 is independently alkyl, alkoxy, hydroxyalkyl, halogen, or hydroxy; and

each R 8 is independently H, halogen, or alkyl optionally substituted with one or more R 5 .

2 . The compound according to claim 1 , wherein:

R 1 is phenyl, 5-6 membered heteroaryl, C 4 -C 10 cycloalkyl, or 5-6 membered heterocycloalkyl,

wherein R 1 is substituted 0-4 G 2 groups,

each G 2 is independently selected from halogen, OH, CN, C 1 -C 6 alkyl optionally substituted with 1-3 R 5 , C 1 -C 6 alkoxy optionally substituted with 1-3 R 5 ;

each R 2 is independently H, halogen, or CH 3 ;

R 3 is H, halogen C 1 -C 3 alkyl, C 1 -C 3 hydroxyalkyl, or C 1 -C 3 haloalkyl;

L is —O—, —OCH 2 —, —N(H)—, —N(CH 3 )—, —N(H)—C(R 8 ) 2 , —[(CR 8 ) 2 ] 1-2 —, —C(R 8 ) 2 O—, or —C(R 8 ) 2 —N(H);

R 4 is H, halogen, C 1 -C 6 alkyl, C 1 -C 6 hydroxyalkyl, 4-6 membered heterocycloalkylalkyl, 5-6 membered heteroarylalkyl, or —C 1 -C 6 alkyl-N(R 6 ) 2 , wherein each C 1 -C 6 alkyl, C 1 -C 6 hydroxyalkyl, 4-6 membered heterocycloalkylalkyl, 5-6 membered heteroarylalkyl, or -alkyl-N(R 6 ) 2 is optionally substituted with 1-3 R 7 ;

each R 5 is independently halogen C 1 -C 3 haloalkyl, or OH;

each R 6 is independently H or C 1 -C 6 alkyl optionally substituted with 1-3 R 5 ;

each R 7 is independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 hydroxyalkyl, halogen, or hydroxy; and

each R 8 is independently H, halogen, or C 1 -C 6 alkyl optionally substituted with 1-3 R 5 .

3 . The compound according to claim 2 , wherein:

R 1 is phenyl, 5-6 membered heteroaryl, C 4 -C 10 cycloalkyl, or 5-6 membered heterocycloalkyl, wherein R 1 is substituted 0-3 G 2 groups,

each G 2 is independently selected from Cl, F, OH, CN, C 1 -C 4 alkyl optionally substituted with 1-3 R 5 , C 1 -C 4 alkoxy optionally substituted with 1-3 R 5 ;

each R 2 is independently H, Cl, F, or CH 3 ;

R 3 is H, Cl, F, C 1 -C 2 alkyl, C 1 -C 2 hydroxyalkyl, or C 1 -C 2 haloalkyl;

L is —O—, —OCH 2 —, —N(H)—, or N(H)C(H) 2 ;

R 4 is H, F, Cl, C 1 -C 4 alkyl, C 1 -C 4 hydroxyalkyl, 4-6 membered heterocycloalkylalkyl, 5-6 membered heteroarylalkyl, or —C 1 -C 4 alkyl-N(R 6 ) 2 , wherein each C 1 -C 4 alkyl, C 1 -C 4 hydroxyalkyl, 4-6 membered heterocycloalkylalkyl, 5-6 membered heteroarylalkyl, or—C 1 -C 4 alkyl-N(R 6 ) 2 is optionally substituted with 1-3 R 7 ;

each R 5 is independently Cl, F, or OH;

each R 6 is independently H or C 1 -C 4 alkyl optionally substituted with 1-3 R 5 ;

each R 7 is independently C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 hydroxyalkyl, Cl, F, or hydroxy; and

each R 8 is independently H, halogen or C 1 -C 4 alkyl optionally substituted with 1-3 R 5 .

4 . A compound according to claim 1 having one of the following formulae:

or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog of any of formulae IIa, IIb, IIc, IId or IIe.

5 . The compound according to claim 4 , wherein:

R 1 is phenyl, 5-6 membered heteroaryl, C 4 -C 10 cycloalkyl, or 5-6 membered heterocycloalkyl, wherein R 1 is substituted 0-4 G 2 groups,

each G 2 is independently selected from halogen, OH, CN, C 1 -C 6 alkyl optionally substituted with one or more R 5 , C 1 -C 6 alkoxy optionally substituted with 1-3 R 5 ;

R 2 is H, halogen, or CH 3 ;

R 4 is H, halogen, C 1 -C 6 alkyl, C 1 -C 6 hydroxyalkyl, 4-6 membered heterocycloalkylalkyl, 5-6 membered heteroarylalkyl, or —C 1 -C 6 alkyl-N(R 6 ) 2 , wherein each C 1 -C 6 alkyl, C 1 -C 6 hydroxyalkyl, 4-6 membered heterocycloalkylalkyl, 5-6 membered heteroarylalkyl, or -alkyl-N(R 6 ) 2 is optionally substituted with 1-3 R 7 ;

each R 5 is independently halogen C 1 -C 3 haloalkyl, or OH;

each R 6 is independently H or C 1 -C 6 alkyl optionally substituted with 1-3 R 5 ;

each R 7 is independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 hydroxyalkyl, halogen, or hydroxy; and

each R 8 is independently H, halogen, or C 1 -C 6 alkyl optionally substituted with 1-3 R 5 .

6 . The compound according to claim 5 , wherein:

R 1 is phenyl, 5-6 membered heteroaryl, C 4 -C 10 cycloalkyl, or 5-6 membered heterocycloalkyl, wherein R 1 is substituted 0-3 G 2 groups,

each G 2 is independently selected from Cl, F, OH, CN, C 1 -C 4 alkyl optionally substituted with one or more R 5 , C 1 -C 4 alkoxy optionally substituted with 1-3 R 5 ;

R 2 is H, Cl, F, or CH 3 ;

R 4 is H, F, Cl, C 1 -C 4 alkyl, C 1 -C 4 hydroxyalkyl, 4-6 membered heterocycloalkylalkyl, 5-6 membered heteroarylalkyl, or —C 1 -C 4 alkyl-N(R 6 ) 2 , wherein each C 1 -C 4 alkyl, C 1 -C 4 hydroxyalkyl, 4-6 membered heterocycloalkylalkyl, 5-6 membered heteroarylalkyl, or—C 1 -C 4 alkyl-N(R 6 ) 2 is optionally substituted with 1-3 R 7 ;

each R 5 is independently Cl, F, or OH;

each R 6 is independently H or C 1 -C 4 alkyl optionally substituted with 1-3 R 5 ;

each R 7 is independently C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 hydroxyalkyl, Cl, F, or hydroxy; and

each R 8 is independently H, halogen, or C 1 -C 4 alkyl optionally substituted with 1-3 R 5 .

7 . The compound according to claim 6 , wherein R 1 is phenyl or pyridyl substituted with 1-3 groups independently selected from Cl, F, CF 3 and CN.

8 . The compound according to claim 7 , wherein R 1 is phenyl or pyridyl, wherein the phenyl or pyridyl is substituted with 1 CF 3 and optionally substituted with 1-2 F.

9 . A formic acid salt according to the compound according to claim 1 .

10 . A compound selected from Table 1, or a pharmaceutically acceptable salt thereof.

11 . A pharmaceutical composition comprising a compound according to claim 1 , and a pharmaceutically acceptable carrier.

12 . The pharmaceutical composition of claim 11 , further comprising a second pharmaceutical agent.

13 . A method for treating a subject with a disease or condition mediated by YAP/TEAD, said method comprising administering to the subject an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt, deuterated analog, a tautomer or a stereoisomer thereof.

14 . A method for treatment of a disease or condition according to claim 13 , wherein the disease or condition is a cancer, a neurodegenerative disease, a heart related disorder, or a kidney-related disorder.

15 . A method for treatment of a disease or condition according to claim 13 , wherein the disease or condition is polycystic kidney disease, Alzheimer's disease, arrhythmogenic cardiomyopathy, Holt-Oram syndrome, liver cancer, epithelioid hemangioendothelioma, breast cancer, lung cancer, malignant mesothelioma, pancreatic cancer, Kaposi sarcoma, uveal melanoma, renal cell carcinoma, colorectal cancer, multiple myeloma, neurofibromatosis Type 2, glioma, or glioblastoma.

16 . The method according to claim 13 , further comprising administering one or more additional therapeutic agents.

17 . The method according to claim 16 , wherein the one or more additional therapeutic agents is one or more of i) an alkylating agent selected from adozelesin, altretamine, bizelesin, busulfan, carboplatin, carboquone, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, estramustine, fotemustine, hepsulfam, ifosfamide, improsulfan, irofulven, lomustine, mechlorethamine, melphalan, oxaliplatin, piposulfan, semustine, streptozocin, temozolomide, thiotepa, and treosulfan; ii) an antibiotic selected from bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, menogaril, mitomycin, mitoxantrone, neocarzinostatin, pentostatin, and plicamycin; iii) an antimetabolite selected from azacitidine, capecitabine, cladribine, clofarabine, cytarabine, decitabine, floxuridine, fludarabine, 5-fluorouracil, ftorafur, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, nelarabine, pemetrexed, raltitrexed, thioguanine, and trimetrexate; iv) an immune checkpoint agent selected from a PD-1 inhibitor, a PD-L1 inhibitor, and an anti-CTLA4 inhibitor; v) a hormone or hormone antagonist selected from enzalutamide, abiraterone, anastrozole, androgens, buserelin, diethylstilbestrol, exemestane, flutamide, fulvestrant, goserelin, idoxifene, letrozole, leuprolide, magestrol, raloxifene, tamoxifen, and toremifene; vi) a taxane selected from DJ-927, docetaxel, TPI 287, paclitaxel and DHA-paclitaxel; vii) a retinoid selected from alitretinoin, bexarotene, fenretinide, isotretinoin, and tretinoin; viii) an alkaloid selected from etoposide, homoharringtonine, teniposide, vinblastine, vincristine, vindesine, and vinorelbine; ix) an antiangiogenic agent selected from AE-941 (GW786034, Neovastat), ABT-510, 2-methoxyestradiol, lenalidomide, and thalidomide; x) a topoisomerase inhibitor selected from amsacrine, edotecarin, exatecan, irinotecan, SN-38 (7-ethyl-10-hydroxy-camptothecin), rubitecan, topotecan, and 9-aminocamptothecin; xi) a kinase inhibitor selected from erlotinib, gefitinib, flavopiridol, imatinib mesylate, lapatinib, sorafenib, sunitinib malate, 7-hydroxystaurosporine, and vatalanib; xii) a targeted signal transduction inhibitor selected from bortezomib, geldanamycin, and rapamycin; xiii) a biological response modifier selected from imiquimod, interferon-α and interleukin-2; xiv) an IDO inhibitor; xv) a chemotherapeutic agent selected from 3-AP (3-amino-2-carboxyaldehyde thiosemicarbazone), altrasentan, aminoglutethimide, anagrelide, asparaginase, bryostatin-1, cilengitide, elesclomol, eribulin mesylate, ixabepilone, lonidamine, masoprocol, mitoguanazone, oblimersen, sulindac, testolactone, tiazofurin, an mTOR inhibitor, a PI3K inhibitor, a Cdk4 inhibitor, an Akt inhibitor, a Hsp90 inhibitor, a farnesyltransferase inhibitor and an aromatase inhibitor (anastrozole letrozole exemestane); xvi) a BRAF inhibitor; xvii) a Mek inhibitor; xviii) c-Kit mutant inhibitor, xix) an EGFR inhibitor, xx) an epigenetic modulator; xxi) other adenosine axis blockade agents selected from CD39, CD38, A2AR and A2BR; or xxii) agonists of TNFA super family member; and xxiii) an anti-ErbB2 mAb.